Bedrijfsoverzicht
Enveric Biosciences, Inc. is a biotechnology enterprise dedicated to the development of small-molecule therapeutics designed to address anxiety, depression, and addiction disorders. The company operates within the healthcare sector, specifically focusing on the biotechnology industry, which implies a reliance on extensive research and development cycles to bring novel treatments to market. Its current scale is characterized by a market capitalization of $3.71M and a workforce consisting of 5 employees, indicating a very early-stage operational footprint. The combination of a sub-$4 million market cap and zero reported annual revenue suggests that the company is in a pre-commercial phase, deriving value primarily from its intellectual property pipeline rather than current sales performance. This limited financial scale reflects the typical profile of a company whose assets consist largely of future product candidates, such as EB-002, which is currently in preclinical development as an active metabolite of psilocybin.
Financiële gezondheid
The company reports no revenue in the trailing twelve months, resulting in a net income of $-12,131,472 and an EBITDA of $-8,573,590. The substantial gap between zero revenue and significant net losses reveals a cost structure dominated by operational expenses related to research, clinical trial preparations, and administrative overhead rather than cost of goods sold. Free cash flow stands at $-4,792,909, indicating that the company is currently consuming cash reserves to fund its development activities rather than generating liquidity from operations. This negative cash flow position limits immediate financial flexibility, necessitating a reliance on existing capital or external financing to sustain operations until commercialization milestones are reached. The company maintains gross margins, operating margins, and profit margins all at 0.0%, which is standard for entities with no sales but highlights the absence of profitability in its current business model. On the balance sheet, Enveric holds $4.68M in cash against $0 in debt, creating a highly conservative leverage profile with a debt-to-equity ratio listed as N/A due to the lack of equity value in the traditional sense or zero debt. The current ratio is 5.38, signifying strong short-term liquidity as the company possesses more than five times the current assets required to cover its short-term liabilities. Return on Equity is -304.0% and Return on Assets is -134.1%, metrics that mathematically reflect the total consumption of capital without the generation of earnings to offset these outlays.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is N/A because the company has not generated positive earnings over the last year, while the forward P/E is calculated at -1.39, a metric that is often used cautiously for loss-making companies to project potential future earnings trajectory. The price-to-book ratio is 0.50, indicating that the market values the company at half of its book value, which suggests the market is pricing in significant risks or expects that the asset base may not fully realize its potential value upon commercialization. Alternative valuation metrics such as the price-to-sales ratio are N/A due to the absence of sales, while the EV/EBITDA stands at 0.11, reflecting a valuation based on enterprise value relative to negative earnings before interest, taxes, depreciation, and amortization. The stock has traded within a 52-week range bounded by a high of $17.84 and a low of $1.75, with the current trading price situated well below the 52-week high, reflecting recent market volatility or a pullback from previous peaks. The beta value is 0.33, which indicates that the stock's price volatility is significantly lower than that of the broader market, behaving as a defensive asset despite its high-risk biotechnology sector classification.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both N/A, as the company has not yet achieved commercial sales or consistent profitability to establish a historical growth baseline. Since the company is not a dividend payer, the dividend yield is N/A and the payout ratio is 0.0%, meaning that any available earnings, had they existed, would be retained rather than distributed to shareholders. Instead of paying dividends, the company reinvests all its limited financial resources back into the development of its product candidates to advance them from preclinical stages toward clinical trials and eventual market entry. The overall growth and income profile is characterized by a complete reliance on capital deployment for future growth rather than current income generation or dividend distributions.